Clenbuterol Hydrochloride

Clenbuterol Hydrochloride is a beta-2 adrenoceptor agonist that belongs to the sympathomimetic class of drugs. It has been primarily used as a bronchodilator in the treatment of pulmonary diseases like asthma. By stimulating the beta-2 adrenoceptors in the airways, clenbuterol helps in relaxing and widening the smooth muscles, thereby improving airflow to the lungs.
Interestingly, clenbuterol also exhibits anabolic properties when taken at higher doses. It can act as a potent muscle-building compound by promoting skeletal muscle protein synthesis. This anabolic effect aids in increasing muscle mass and strength, while simultaneously reducing the deposition of fat in the body.
In summary, clenbuterol hydrochloride serves a dual purpose. At therapeutic doses, it functions as a bronchodilator to alleviate respiratory conditions. However, at elevated doses, it acts as an anabolic steroid, facilitating muscle protein synthesis and enhancing muscular development.

>98%

store at -20° C for one year（Powder）；
To maintain stability, it is recommended to store the substance in DMSO or other solvents at a temperature range of 2-4° C for up to two weeks. If long-term storage is necessary, freezing at a temperature of -20° C is recommended for up to six months. These storage conditions are crucial to ensure the integrity and quality of the substance over time.

DMSO

Adrenergic Receptor

In rat primary adipocytes, the presence of Clenbuterol significantly enhances the breakdown of fats, specifically through the process of lipolysis. When compared to the control group, the release of free glycerol into the culture medium is substantially elevated. In cultures containing 0.1 μM Clenbuterol, the level of free glycerol release is 158% higher than the control values. Furthermore, in cultures with 1 μM Clenbuterol, the increase in free glycerol release reaches 190% of the control values. These findings highlight the potent impact of Clenbuterol on stimulating lipolysis in rat primary adipocytes.

Clenbuterol has been found to have fat-reducing effects in animals by inducing apoptosis in adipose tissue in mice. Interestingly, it also affects the mitochondrial content and various proteins involved in fatty acid and glucose transport and oxidation in both red and white muscles. These metabolic changes are associated with decreased levels of PGC-1α and increased levels of RIP140.
Furthermore, when Clenbuterol is repeatedly administered to rats, it reduces the ability of isoproterenol to increase cyclic AMP concentration in cerebellum slices. This reduced responsiveness to isoproterenol is accompanied by a significant decrease in the density of beta adrenoceptors.
In normal soleus muscle, Clenbuterol treatment has shown to stimulate protein synthesis, inhibit Ca2+-dependent proteolysis, and elevate levels of calpastatin protein. However, in DEN rats, Clenbuterol administration has demonstrated positive effects by improving muscle mass loss, increasing protein synthesis rate, reducing hyperactivation of proteasomal and lysosomal proteolysis, and suppressing the transcription of certain lysosomal proteases such as cathepsin L, atrogin-1/MAFbx, and MuRF1.
By rearranging the information, we can summarize the key findings of Clenbuterol as follows:
- Clenbuterol decreases body fat in animals.
- It induces apoptosis in adipose tissue in mice.
- Clenbuterol leads to reduced mitochondrial content and affects various proteins involved in fatty acid and glucose transport and oxidation in red and white muscles.
- These metabolic changes are associated with decreased PGC-1α and increased RIP140 levels.
- Repeat administration of Clenbuterol to rats reduces the responsiveness to isoproterenol and decreases the density of beta adrenoceptors.
- In normal soleus muscle, Clenbuterol stimulates protein synthesis, inhibits Ca2+-dependent proteolysis, and increases calpastatin protein levels.
- In DEN rats, Clenbuterol improves muscle mass loss, enhances protein synthesis rate, reduces proteolysis, and suppresses transcription of certain lysosomal proteases.